CN Patent

CN109384712A — 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用

Assigned to Beijing Generous Pharmaceutical Technology Co Ltd · Expires 2019-02-26 · 7y expired

What this patent protects

本发明涉及靶向NK1受体拮抗剂及其在化疗所致恶心，呕吐治疗中的应用，属于肿瘤化疗辅助治疗药物技术领域。本发明提供下式I所示的化合物、其消旋体、立体异构体、互变异构体、同位素标记物、氮氧化物或其药学上可接受的盐： 本发明还提供所述化合物的制备方法、药物组合物和用途。

USPTO Abstract

本发明涉及靶向NK1受体拮抗剂及其在化疗所致恶心，呕吐治疗中的应用，属于肿瘤化疗辅助治疗药物技术领域。本发明提供下式I所示的化合物、其消旋体、立体异构体、互变异构体、同位素标记物、氮氧化物或其药学上可接受的盐： 本发明还提供所述化合物的制备方法、药物组合物和用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN109384712A
Jurisdiction
CN
Classification
—
Expires
2019-02-26
Drug substance claim
No
Drug product claim
No
Assignee
Beijing Generous Pharmaceutical Technology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.